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lobal cancer statistics demonstrate an
approximate annual incidence for renal cell
carcinoma (RCC) of 271,000 cases in 2008.1
The incidence of RCC is rising. Within the male
population of developed countries it is now the sixth
most common cancer, with an estimated 111,100
new cases and a mortality of 43,000 in 2008.2 ActiveAuthors. Published by Elsevier Inc.
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cense.and passive smoking, hypertension, and obesity
have been identified as risk factors for RCC and
contribute to the increasing incidence. In addition,
increasingly common use of medical imaging, such
as ultrasonography, magnetic resonance imaging
(MRI), and computed tomography (CT), has led to
rising incidental detection rates of RCC.3 Conse-
quently, many patients are now diagnosed with
asymptomatic early-stage RCC. A 2008 quantitative
analysis of the US National Cancer Data Base
revealed that 50.6% of patients had stage I, 26.7%
stages II and III, and 22.7% stage IV (metastatic) RCC
at presentation.4
Due to the increasing number of patients with
stages I–III RCC, optimizing the management of early-
stage RCC is one of the key priorities in the onco-
logical clinical practice. It is well established that
radical surgical resection is curative for a proportion
of these patients. This surgery can be performed in a
nephron-sparing procedure with optional regional
lymph node dissection, or by open or laparoscopic
nephrectomy. After surgery, patients with stage I
RCC have a 5-year survival of490%, but the 5-year
relapse rate after surgical excision in patients with
stage II or III disease is 30%–40%.5 The median time
to relapse is 18 months and the majority of relapses
occur within 3 years of surgical resection.
In addition to surgical management, relapse risk
reduction through adjuvant therapy is thus a very
important goal in patients with intermediate- andars in Oncology, Vol 40, No 4, August 2013, pp 482-491
Adjuvant therapy in renal cell carcinoma 483high-risk early-stage RCC. However, despite signifi-
cant efforts, no effective adjuvant therapy has been
developed to date. This is in contrast to a number of
clinically proven therapies for stage IV RCC.
This publication discusses the past, present, and
future of adjuvant treatment in RCC. It summarizes
risk stratification prior to adjuvant trial enrollment,
important completed negative adjuvant clinical trials
with a focus on immune therapies, the current
adjuvant clinical trial landscape with a focus on
targeted anti-angiogenic therapies, and potential
future trial medications and trial designs.RISK STRATIFICATION PRIOR TO ADJUVANT
TREATMENT IN RCC
When considering adjuvant treatment, correct
patient selection is very important. As described
above, some patients with early-stage RCC have a
relapse risk of up to 40% and could therefore benefit
substantially from successful adjuvant treatment. On
the other hand, unnecessary treatment exposes
patients to the risks of the therapies and their
unwanted side effects and this risk must be mini-
mized. Several predictive and prognostic scoring
systems have been developed that can guide the
enrollment of patients into adjuvant trials in RCC.
For localized disease, the stage, size, grade, and
necrosis (SSIGN) score (also known as the Leibovich
score), developed at the Mayo Clinic, is particularly
useful for predicting 5-year metastasis-free survival.6,7
It was initially derived by correlating the relapse rate
of 1,801 patients over a mean period of 9.7 years to
the category of the primary tumor, regional lymph
node status, tumor size, and the presence or absence
of tumor necrosis on histopathological examination.
Tumor necrosis is not clearly defined and is not
consistently included in histopathological reports at
all centers and thus presents a small limitation of the
SSIGN score. Based on the final SSIGN score, patients
are classified into low-, intermediate-, or high-risk
categories for disease relapse.Figure 1. Timeline for licensed therapies for metastatic RCC a
preceded targeted anti-angiogenesis therapies both in terms
research for adjuvant benefit. Adjuvant trials with immune ther
are not completed yet. FDA, US Food and Drug Administration
target of rapamycin; TKI, tyrosine kinase inhibitor; VEGF, vascul
Future Medicine Ltd.48The Integrated Staging System developed at the
University of California Los Angeles (UISS) defines
low-, intermediate-, or high-risk prognostic groups
based on tumor, node, metastasis (TNM) staging,
Fuhrman grade, and Eastern Cooperative Oncology
Group (ECOG) performance status. It is validated for
classification of patients with localized and metastatic
disease.8,9 In a direct comparison within a small
patient cohort, the UISS system showed a slightly
inferior accuracy in stratifying relapse risk of patients
with clear cell RCC than the SSIGN system.10 Among
the current adjuvant clinical trials there are examples
of trials based on either system and their analyses will
further guide future risk stratification.GENERAL CONSIDERATIONS FOR ADJUVANT
CLINICAL TRIALS IN RCC
Apart from accurate risk stratification and correct
inclusion and exclusion criteria for adjuvant clinical
trials, the choice of treatment is paramount. In
general, adjuvant treatment in oncology is guided
by effective treatments for metastatic disease. Stage
IV RCC has been treated successfully with immune
therapy and, more recently, with targeted therapies,
such as vascular endothelial growth factor (VEGF)
receptor–targeted tyrosine kinase inhibitors (TKIs),
VEGF antagonists, and mammalian target of rapamy-
cin (mTOR) inhibitors. Figure 1 summarizes the
timeline of licensed medications for treatment of
stage IV RCC and the corresponding timeline for
past and current adjuvant clinical trials. These are
discussed in detail below.
Completed Adjuvant Clinical Trials in RCC
Using Immune Therapy—The Past I
Before the clinical introduction of targeted thera-
pies, cytokine-based immunotherapy with interleukin-
2 (IL-2) and/or interferon-alfa (IFN-α) was the standard
therapy for stage IV RCC (Table 1). Treatment using
IL-2 alone, IFN-α alone, or IL-2 in combination with
IFN-α achieved objective response rates (RRs)nd correlating adjuvant clinical trials. Immune therapies
of approval for treatment of metastatic disease and in
apy were not successful and those with targeted agents
; IFN, interferon; IL-2, interleukin 2; mTOR, mammalian
ar endothelial growth factor. Adapted with permission of
Table 1. Adjuvant Trials in RCC Using Immune Therapies Ordered by Appearance in the Text
Authors Intervention Patient Population Design No. of Patients Outcome
Pizzocarro
et al15
IFN-α2b v placebo Robson stages II and III (T3aN0M0
and T3bN0M0 or T2/3N1-3M0)
Multicenter,
randomized,
controlled trial
247 5-year OS: 0.665 (control) v 0.660 (treatment) (HR
1.040; 95% CI, 0.671 - 1.613, P ¼ 0.861)
5-year DFS: 0.671 (control) v 0.567 (treatment) (HR
1.412; 95% CI, 0.927–2.149, P ¼ .107)
Messing
et al16
IFN-α-NL v observation pT3–4a and/or node-positive) Multicenter,
randomized,
controlled trial
283 At 10.4 years median follow-up:
Median survival: 7.4 years (control) v 5.1 years
(treatment) (P ¼ .09).
DFS: 3.0 years (control) v 2.2years (treatment)
(P ¼ .33)
Clark et al17 IL-2 v observation T3b-4 or N1–3 (LA) or M1 Multicenter,
randomized,
controlled trial
69 total; 44 LA,
25 M1
disease
2-year DFS: 48% (control in LA patients) v 53%
(treatment in LA patients) (P ¼ 0.73)
2-year OS: 77% (control in LA patients) v 86%
(treatment in LA patients) (P ¼ .38)
Passalacqua
et al18
IL-2 and IFN-α v observation pT1, T2, T3 a-b-c; pN0-pN3, M0 Multicenter,
randomized,
controlled trial
310 5-year DFS: 0.73 (control) v 0.73 (treatment)
10-year DFS: 0.60 (control) v 0.73 (treatment)
(HR 0.84; 95% CI, 0.54–1.33, P ¼ 0.47)
Atzpodien
et al19
IL-2 and IFN-α2a and
intravenous 5 v fluorouracil
pT3b/c pN0 or pT4pN0), pN,
complete
resection of tumor relapse or
solitary metastasis (R0)
Multicenter,
randomized,
controlled trial
203 At median follow-up of 4.3 years:
2-year OS: 91% (control) v 81% (treatment)
5-year OS: 76% (control) v 58% (treatment)
8-year OS: 66% (control) v 58% (treatment)
(P ¼ 0.0278)
2-year DFS: 62% (control) v 54% (treatment)
5-year DFS: 49% (control) v 42% (treatment)
8-year DFS: 49% (control) v 39% (treatment)
(P ¼ 0.2398)
Aitchison
et al22
IL-2 and IFN-α2a and intravenous 5-fluorouracil T3b-c,T4 or any pT and pN 1 or
pN 2 or positive microscopic
margins or microscopic vascular
invasion
Multicenter,
randomized,
controlled trial
309 3-year DFS: 50% (control) v 60% (treatment) (HR
0.87; 95% CI, 0.63-1.20)
5 year OS: 60% (control) v 68% (treatment) (HR 0.91;
95% CI, 0.60–1.38)
Galligioni
et al24
Autologous irradiated tumor cells & BCG v
observation
Stages I, II, and III Prospective,
randomized,
controlled trial
120 At 61 months median follow-up:
5-year OS: 78% (control) v 69% (treatment)
5-year DFS: 72% (control) v 63% (treatment)
Adler et al25 Autologous irradiated tumor cells & BCG &
hormone v hormone
All stages Prospective,
randomized,
controlled trial
43 Trend for prolongation of DFS for stage I, II, and III
(Po.1)
Wood
et al26
Autologous, tumor-derived heat-shock
protein (glycoprotein 96)–peptide complex
(HSPPC-96; vitespen) v observation
cT1b–T4 N0 M0, or cT any N1-2 M0 Multicenter,
randomized,
controlled trial
819 At 1.9 years median follow-up:
Recurrence: 39.8% (control) v 37.7% (treatment) (HR
0·923; 95% CI, 0·729–1·169, P ¼ .506)
OS not mature
Jocham
et al27
Autologous renal tumor cells (Reniale) pT2–3b pN0–3 M0 Multicenter,
randomized,
controlled trial
558 At 5-year follow-up:
DFS: 67.8% (control) v77.4% (treatment) (P ¼ .0204)
At 70-month follow-up:
DFS: 59.3% (control) v 72% (treatment)
HR for tumor progression: 1.58 (95% CI 1.05–2.37)
and 1.59 (1.07–2.36) (P ¼ .0204)
Note. The table includes trials with cytokines and vaccines.
Abbreviations: IFN, interferon; IL, interleukin; NL, neutral lymphoblastoid; LA, locally advanced; BCG, bacillus Calmette-Guérin; CI, conﬁdence interval; LA, locally advanced; HR, hazard
ratio; M, metastatic; OS, overall survival; DFS, disease-free survival.
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Adjuvant therapy in renal cell carcinoma 485between 15% and 31% in stage IV RCC.11–14 These
results formed the basis for several adjuvant clinical
trials with immune therapies in RCC. Theoretically,
immune therapy could be considered most effe-
ctive in small-volume disease. The adjuvant setting is
therefore particularly relevant as it can be considered
treatment of potential micro-metastatic disease.
None of these adjuvant trials, however, demon-
strated statistically significant improvement of disease-
free survival (DFS) or overall survival (OS) (see
Table 1 for details). Two adjuvant trials using IFN-
α,15,16 as well as one study that used high-dose bolus
IL-2,17 were negative. The latter study was designed
and powered to show an improvement in predicted
2-year DFS from 40% for the observation group to 70%
for the treatment group. Early closure occurred when
an interim analysis determined that the 30% improve-
ment in 2-year DFS could not be achieved despite full
accrual. Combination treatment of IL-2 and IFN-α
equally failed to improve DFS in one adjuvant trial.18
The combination of cytokines with 5-fluorouracil
(5-FU) enhances objective RRs to between 18% and
39% in metastatic RCC19,20; however, it failed to
improve DFS in the adjuvant setting.21,22 In one
randomized adjuvant trial, triple combination ther-
apy using IL-2, IFN-α, and 5-FU was associated with
significant toxicity (92% of patients had grade 2 and
41% had grade 3 toxicities, leading to 35% of patients
not completing treatment) but resulted in no benefit
in DFS or OS.22
All of the clinical trials used observation as the
control arm and all excluded patients with meta-
static disease apart from the trial on high-dose IL-2.17
Sample size for each study was calculated to detect
the respective primary endpoint (either progression-
free survival [PFS] or OS). It is important to note that
these clinical trials were designed and completed
before any validated stratification system for recur-
rence risk was established. Patient recruitment was
mainly based on histopathological parameters and
results may have been different if the SSIGN or UISS
systems had been used for risk stratification.
Therapeutic vaccines also have been tested in
adjuvant trials in RCC23 (see Table 1 for details).
Autologous irradiated tumor cells mixed with bacillus
Calmette-Gue´rin (BCG) was tested in two randomized
trials and did not result in prolonged DFS.24,25 Sim-
ilarly, autologous, tumor-derived heat-shock protein
(glycoprotein 96)–peptide complex (HSPPC-96;
vitespen) did not result in a statistically significant
improvement of DFS.26 A trial with an autologous
renal tumor cell vaccine only reported improved DFS
in the vaccine group,27 but the number of patients lost
after the randomization step, the imbalance of this
loss, and the absence of tabulation of OS led to
criticism of the results.28 This therapy has not been
implemented in routine clinical practice.In conclusion, immune therapy has no proven
role in adjuvant therapy of RCC. Future autologous
vaccine trials will need to be conservatively reported
with the intention-to-treat analysis and the per-
protocol analysis both reported to take into account
the proportion of patients in whom an autologous
vaccine cannot be manufactured.
Completed Adjuvant Clinical Trials in RCC
Using Hormone Therapy or Radiotherapy—
The Past II
RCC has been considered potentially hormone-
responsive since diethylstilbesterol was shown to
induce malignant renal cancers in hamsters.29 Fur-
ther animal studies demonstrated that RCC tumors
were inhibited by hormone therapy. Additionally,
61% and 75% of RCCs have been reported to express
estrogen and androgen receptors, respectively. How-
ever, treatment of RCC using hormone-directed
therapy in patients has been largely unsuccessful
with reported overall RRs between 2% and 6% in
stage IV RCC.29 Despite these results, a prospective
randomized multicenter study comparing adjuvant
medroxyprogesterone acetate treatment for 1 year to
no treatment following radical nephrectomy was
conducted.30 Neither a significant difference in
relapse rate nor correlations between receptors,
relapses and treatment were found.
Radiotherapy can be useful for palliation of symp-
toms (eg, hematuria, painful bone metastases) in
patients with stage IV RCC. Furthermore, long-term
PFS has been reported for in a subset of patients
following radiotherapy for solitary bone metastases.31
However, clinical trials evaluating the role of radio-
therapy in the adjuvant setting revealed disappointing
results. One prospective, randomized study in 72
patients comparing administration of 50 Gy in 20
fractions to the kidney bed, and ipsilateral and con-
tralateral lymph nodes for stages II and III RCC versus
observation reported relapse rates of 48% in both
groups. Forty-four percent of patients in the radio-
therapy arm had significant complications that contrib-
uted to the death of 19% of patients. The authors
concluded that postoperative radiotherapy is without
any beneficial effect on relapse rate and survival and is
associated with an unacceptable complication rate.32,33
Consequently, neither hormone treatment nor
radiotherapy is recommended as adjuvant therapy
in patients with RCC. To our knowledge, neither
treatment modality is currently being investigated in
the adjuvant setting in clinical trials.
Current Adjuvant Clinical Trials in RCC Using
Targeted Therapies—The Present
While adjuvant clinical trials with immune-
directed therapies did not demonstrate clinical
Table 2. Clinical Trials Database (http://clinicaltrials.gov) Listed Large, Multicenter, Placebo-Controlled, Randomized, Double-Blind
Adjuvant Clinical Trials in RCC
Acronym Trial No. Status Intervention Funding Body/Sponsors Design Start Date/
Estimated
Completion
Stratiﬁcation Estimated
Enrollment
Outcome
Measures
ARISER NCT00087022 Reported negative,
press release only
Girentuximab Industry; Wilex MC, DB, R,
PC
07/2004 High-risk patients based
on TN stage or
Fuhrman grade,
ECOG PS¼ 0 or 1
864 Primary endpoint,
DFS, not met10/2012
ASSURE NCT00326898 Active, not recruiting Sorafenib or Sunitinib NIH; NCI, ECOG, SWOG,
Cancer and Leuke-
mia Group B, NCIC
MC, DB, R,
PC
05/2006 At least intermediate
high-risk UISS, ECOG
PS¼ 0 or 1, clear or
non-clear cell RCC
1923 DFS, OS, Toxicity,
QoL04/2016
ATLAS NCT01599754 Recruiting Axitinib Industry; SF J
Pharmaceuticals,
Pfizer
MC, DB, R,
PC
04/2012 High-risk UISS, ECOG
PS¼ 0 or 1,
predominant clear
cell histology
592 DFS, OS, Toxicity
05/2019
PROTECT NCT01235962 Recruiting Pazopanib Industry;
GlaxoSmithKline
MC, DB, R,
PC
11/2010 Modified UISS, Karnofsky
performance scale of
at least 80, clear cell
or predominant clear
cell histology
1500 OS, DFS, Toxicity,
QoL04/2017
SORCE NCT00492258 Recruiting Sorafenib Medical Research
Council UK
MC, DB, R,
PC
05/2007 Intermediate- and high-
risk SSIGN, ECOG
PS¼ 0 or 1, clear or
non-clear cell RCC
1656 OS, DFS, Toxicity
2013
S-TRAC NCT00375674 Active, not recruiting Sunitinib Industry; Pfizer MC, DB, R,
PC
07/2007 High risk UISS, ECOG
PS¼ 0-2,
predominant clear
cell histology
720 DFS, OS, Toxicity
06/2017
SWOG-S0931 NCT01120249 Recruiting Everolimus NIH; SWOG, NCI MC, DB, R,
PC
04/2011 Pathological high or very
high risk, no further
details available,
ECOG PS¼ 0 or 1
1218 OS, DFS, Toxicity
Abbreviations: ARISER, Adjuvant Rencarex Immunotherapy phase III trial to Study Efﬁcacy in non-metastatic RCC; ASSURE, Adjuvant Sorafenib or Sunitinib for Unfavorable Renal
Carcinoma; ATLAS, Adjuvant Axitinib Treatment of Renal Cancer: a Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib v Placebo in Subjects at High Risk of Recurrent RCC;
PROTECT, a Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efﬁcacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally
Advanced RCC Following Nephrectomy; SORCE, a Phase III Randomized Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell
Carcinoma at High or Intermediate Risk of Relapse; S-TRAC, Sunitinib Treatment of Renal Adjuvant Cancer: a Randomized Double Blind Phase 3 Study of Adjuvant Sunitinib v Placebo
in Subjects at High Risk of Recurrent RCC; SWOG-S0931, EVEREST, EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study; DB, double blind; ECOG, Eastern
Cooperative Oncology Group; DFS, disease-free survival; PS, performance score; MC, multicenter; NCI, National Cancer Institute; NIH, National Institute of Health; OL, open label;
OS, overall survival; PC, placebo-controlled; QoL, quality of life; SWOG, Southwest Oncology Group; R, randomized; TN, tumor, node; UISS, UCLA Integrated Staging System.
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Figure 2. Important molecular pathways and drug tar-
gets in RCC. Inactive VHL leads to increased concentra-
tions of HIF-alpha subunits. The PI3K/mTOR pathway also
increases expression of HIF-alpha subunits. The resulting
transcriptional stimulation of the HIF response element
HRE and the rise in VEGF production stimulates endothelial
growth and increased vascular supply to the tumor.
Targeted therapies inhibit a variety of molecules along
the involved signaling cascades in both tumor and
endothelial cells. VHL,Von Hippel Lindau; HIF, hypoxia-
induced factor; HRE, HIF response element; VEGF, vascular
endothelial growth factor; mTOR, mammalian target of
rapamycin; MAPK, mitogen-activated protein kinase.
Adapted with permission of Future Medicine Ltd.48
Adjuvant therapy in renal cell carcinoma 487benefit, they showed that large multicenter adjuvant
clinical trials are feasible in RCC. Consequently, with
the discovery of effective novel targeted therapies, a
set of new well-powered adjuvant trials was
designed (Table 2).
The development of these targeted therapies has
been informed by an improved understanding of the
molecular biology and pathology of RCC, both in the
tumor and in the surrounding epithelial cells
(Figure 2). In the tumor cell, loss of the tumor-
suppressor gene Von Hippel Lindau (VHL) (or its
function),34 and the resulting downstream abnormali-
ties, have been linked to clear cell RCC. VHL loss
leads to increased activity of the hypoxia-induced
factor (HIF) transcription factor35 and ultimately to
overexpression of VEGF. HIF activity can also be
increased via the mTOR pathway.36 Ultimately, this
leads to increased tumor vascularity due to the
endothelial response to VEGF. Rathmell and Nathan-
son have reviewed the molecular biology of RCC in
more detail in this issue.
Various parts of these molecular pathways have
been targeted successfully either by mTOR inhibitors
such as temsirolimus and everolimus, or by bevaci-
zumab, a monoclonal antibody to VEGF, or by intra-
cellular inhibition of VEGF signaling in endothelialcells using TKIs (Figure 2). Multi-targeted TKIs, such
as sorafenib, sunitinib, and pazopanib, target the
intracellular kinase domains of VEGF receptors
(VEGFR1–3), and, in the case of sorafenib, the
downstream kinases RAF and MAPK.37
Clinical trials in stage IV RCC with VEGF TKIs and
bevacizumab have shown significant improvements
in PFS and OS and have led to the regulatory
approval of these drugs to treat patients with stage
IV RCC (Figure 1). They consequently form the main
stem of clinical practice guidelines for first-line
treatment in metastatic disease.38 Everolimus and
axitinib have led to prolongation of PFS in second-
line treatment after first-line treatment with VEGF
antagonists39,40 (see Escudier and Gore in this issue
of Seminars).
These small molecule targeted therapies (TKIs
and mTOR inhibitors) have good oral bioavailability
and therefore lend themselves particularly well to
large multicenter adjuvant clinical trials. In the
metastatic setting they most often lead to static
disease and they are not cytotoxic to the tumor cell.
This may reduce their efficacy in the adjuvant
setting. Nevertheless, there are currently seven large,
multicenter, placebo-controlled, double-blind,
randomized adjuvant clinical trials are in progress
in RCC. Five of them use TKIs, one an mTOR
inhibitor, and one a monoclonal chimeric antibody
(mAb) to carbonic anhydrase IX. These trials are
listed alphabetically below and with more detail in
Table 2.ARISER (NCT00087022)
This trial investigates girentuximab, a mAb to
carbonic anhydrase IX, a HIF downstream target
gene. It has completed recruitment and has not
met the primary endpoint. The treatment had no
beneficial effect on DFS.41ASSURE (NCT 00326898)
This trial has two experimental arms comparing
sunitinib and sorafenib. The primary endpoint is
DFS. The study is active but no longer recruiting
and completion is estimated for 2016.ATLAS (NCT01599754)
Patients in the experimental arm of this trial
receive axitinib 5 mg twice daily. The primary
endpoint is DFS. It started recruitment in April
2012 and is expected to complete for the primary
end point of DFS in 2017. The study centers are in
Japan and the study population is therefore East
Asian. This may have an impact on the toxicity
profile.
T. Janowitz et al488PROTECT (NCT01235962)
Patients in the experimental arm in this trial
receive 800 mg of pazopanib daily. The primary
endpoint is DFS after 4.5 years of follow-up and
completion is expected for 2017.
SORCE (NCT00492258)
This trial has two experimental arms. Patients
either receive sorafenib for 1 or 3 years. Relapse
risk prior to trial enrollment is calculated using the
SSIGN score. The primary endpoint is DFS. Enroll-
ment is likely to be completed in 2013.
S-TRAC (NCT00375674)
Patients in the experimental arm of this trial
receive sunitinib. The trial uses the UISS score for
risk stratification. The primary endpoint is DFS and
the primary analysis is expected in 2017.
SWOG-S0931 (EVEREST; NCT01120249)
This trial is the only large adjuvant trial investigat-
ing an mTOR inhibitor. Patients on the treatment
arm of this trial receive 12 months of everolimus.
The primary endpoint is DFS. The trial started in
2011 and is not expected to complete until 2021.
A number of smaller adjuvant clinical trials are also
listed on the Clinical Trials register (www.clinical
trials.gov), such as the AGuo trial (NCT01041482).
This trial, for example, investigates sorafenib in a
small cohort of patients using an open-label design.
These trials may add to our understanding of adjuvant
treatment in RCC, but they do not fulfill the require-
ments of high-level clinical evidence and therefore
will not be discussed further in this publication.
As detailed in Table 2, a number of the six large
adjuvant trials with small molecules have been open
for several years. While official reports on endpoints
are still outstanding, some important aspects have
become apparent over time. In particular, trials with
VEGF TKIs have had an unexpectedly high drop-out
rate due to toxicity. The side effect profile of the
TKIs used in these trials includes a number of off-
target effects such as hypothyroidism, liver toxicity,
palmar and plantar erythema, rash, mucositis, ano-
rexia, tiredness, and diarrhea. These are observed
both in the treatment of patients with stage IV
disease and in the adjuvant setting but seem to be
harder to tolerate in the adjuvant setting. They add
to the on-target side effects of proteinuria and
hypertension, mediated by endothelial remodelling.
Most of the trial protocols exclude patients with
uncontrolled hypertension or coronary artery dis-
ease in anticipation of endothelial side effects. The
off-target effects and their severity, however, aremore difficult to predict. In the SORCE trial, for
example, an initial toxicity rate of 20% was predicted
from sorafenib use in the advanced setting, but early
analysis revealed a toxicity rate of 35%. ASSURE
investigators have reported similar findings. Addi-
tionally, both trials have implemented a lead-in
period of half-dose trial medication, as the majority
of toxicities resulting in discontinuation of trial
participation were observed in the first 12 weeks.
In this issue of Seminars, Kollmannsberger et al
discuss the management of treatment-related toxicities
and expert consensus also has been published by
leading clinicians in the field in early 2012.42 More
successful management of toxicity can be expected to
have a positive impact on adjuvant clinical trial enroll-
ment and drop-out rates. Equally, an understanding of
the correct dosage for adjuvant treatment may help to
reduce toxicity. Many of the current adjuvant trials use
the same dose as licensed for palliative treatment of
stage IV disease. Smaller doses may be sufficient to
improve DFS and will reduce toxicity.
The potential long-term side effects of VEGF-
targeted therapy remain unknown and will require
prolonged follow-up from these trials. The potential
for long-term unexpected side effects as seen in the
adjuvant studies in breast cancer is apparent.Upcoming Adjuvant Trial Medications in RCC
—The Future Part I
Translational efforts in adjuvant trials are based on
the molecular preclinical and clinical understanding of
the disease and on knowledge gained during develop-
ment of the treatments in stage IV disease. The future
adjuvant clinical trial landscape in RCC will therefore
be informed by the increasing understanding of the
molecular pathology of RCC and by the emerging
clinical evidence for treatment of metastatic RCC.
A number of molecular drug targets have been
identified and are in phase II/III clinical trials for
stage IV RCC. In January 2013, ClinicalTrials.gov
listed 139 open and active phase II/III clinical trials
for RCC. A recent detailed review of these trials
identified 11 novel targeted agents.43 These include
new TKIs with in addition to Akt inhibitors. In
preclinical studies, pathways such as the HIF path-
way are of interest and may provide further drug
targets.44 There is also evidence that novel immune
therapy may contribute to the future treatments in
RCC. Preliminary data suggest that an anti pro-
grammed death 1 protein ligand (PD-L1) antibody
is safe and may induce tumor regression in RCC.45
Further immune therapies are discussed by McDer-
mott and Atkins in this issue of Seminars.
Furthermore, there is an emerging interest in
combination therapy in metastatic renal cancer
(see Ravauld and Bellmunt this issue). This includes
Adjuvant therapy in renal cell carcinoma 489the combination of TKIs with immune therapies (eg,
NCT01513187: Pazopanib with Interferon Alfa 2-A),
combination of TKIs with chemotherapeutics (eg,
NCT00556049: Sunitinib with Gemcitabine), and the
combination of anti-VEGF antibodies and mTOR
inhibitors (eg, NCT01399918: Bevacizumab and
Everolimus). All of these treatments may be of
interest for future adjuvant trials in RCC if they are
found to be effective in stage IV disease. However,
they may be more toxic, making them less suitable in
particular for adjuvant treatment.Figure 3. Schematic comparison of traditional and
MAMS trial design. Testing three experimental treat-
ments with traditional trial design requires more time
and more control arm enrollment than MAMS trial
design. Separate analysis and design of phase II and
phase III trials makes the traditional trial design process
also less efficient in terms of cost and administrative
effort. Additional points of analysis allow for early
termination of non-effective experimental treatments in
MAMS trials. MAMS, multi-arm multi-stage; C, control/
placebo arm; D, drug/experimental arm; P, point of
primary analysis; S, point of secondary analyses.
Adapted with permission of Future Medicine Ltd.44Considerations Regarding Adjuvant Trial
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The above list of new therapeutic approaches is
not complete. However, even from these examples
it is evident that there will be a multitude of
potential candidate treatments and regimens for
novel adjuvant clinical trials in RCC. As a conse-
quence of the numerous possibilities for adjuvant
clinical trials, challenges arise for adequate trial
design and patient allocation to ensure sufficiently
powered trials and interpretable results. In addition
to the risk stratification systems discussed above,
validated biomarkers of disease recurrence may
facilitate patient allocation and stratification in future
trials. These biomarkers could be cross-validated in
adjuvant trials after initial implementation in inter-
ventional trials for stage IV disease. Both molecular
markers and clinical markers of disease response are
discussed in separate papers in this issue (see Garcia-
Donas and Jonasch, and Michaelson and Stadler).
Future adjuvant clinical trials should draw on knowl-
edge of these markers and also should include
translational endpoints to enable validation in the
context of disease recurrence. Biomarkers and mon-
itoring of drug levels also may guide prediction of
toxicity profiles and could therefore contribute to
reducing trial drop-out rates.
The problem of multiple therapeutic hypotheses is,
of course, not unique to RCC and future adjuvant
clinical trials in RCC can be modeled on novel
adjuvant and non-adjuvant trial designs in other dis-
eases. Multi-arm multi-stage (MAMS) trial design, for
example, offers an alternative to the traditional clinical
trial design (Figure 3) of testing each therapy or
combination therapy in separate trials.46 In a MAMS
trial the experimental arms for several treatments
share one control arm, therefore reducing the number
of patients enrolled in nontreatment parts of clinical
trials, which is also a significant advantage from the
patient perspective. Early and repeated interim analy-
ses that expedite discontinuation of ineffective treat-
ments minimize the number of patients recruited to
non-beneficial intervention. Importantly, early analysis
allows timely discontinuation and publication of thetrial, in case of sufficient evidence for efficacy. MAMS
trial design can therefore deliver conclusive results on
the multiple experimental treatments with signifi-
cantly reduced enrolment numbers. In addition,
MAMS trials reduce the time requirement for clinical
trials by rolling phase II into phase III trials, providing
the interim analysis is favorable. Biomarkers of relapse
could shorten the required time period to interim
analyses further. This also reduces the administrative
effort and the cost for the clinical trial. Finance, ethics
applications, and research and development applica-
tions all can be unified rather than being separately
submitted for phase II and phase III.
These theoretical advantages are currently deliv-
ered in the Medical Research Council STAMPEDE trial,
which compares hormone alone with a combination
of hormone therapy and either zoledronic acid, doce-
taxel (or both), celecoxib, or abiraterone in prostate
cancer.47 This trial had one treatment arm discontin-
ued after interim analyses and also one addition of an
experimental arm. It has thus demonstrated that
MAMS trials are feasible and may accelerate progress
if multiple treatment options are to be evaluated.
We suggest that future adjuvant clinical trials
should incorporate the lessons from the past, such
as anticipation of side effects, in addition to the
innovation of new therapeutic discovery, novel bio-
markers, and trial design. Considering the advances in
these fields, it is very likely that the next few years
will see growing interest in adjuvant clinical trials.
T. Janowitz et al490CONCLUSION
Consensus guidelines recommend consideration
of clinical trial enrollment to deliver potential adju-
vant treatment to patients with intermediate or high
relapse risk from early-stage RCC.5 These recommen-
dations reflect the unmet requirement for relapse
risk reduction. The need for improved adjuvant
treatment is amplified by an increasing incidence
of early stage RCC. Unfortunately, success in the
treatment of metastatic RCC with immune therapy
has not yet been successfully translated into adjuvant
treatment. The results of seven large, multicenter,
placebo-controlled, double-blind, randomized adju-
vant trials investigating the potential benefit of
targeted anti-angiogenesis therapies are expected
over the coming years.
Further understanding of the molecular pathology
of RCC and new therapeutic success in metastatic
RCC will generate future hypotheses for adjuvant
clinical studies. New immune therapies and success-
ful combination therapies will add to this pool of
suitable adjuvant candidate therapies. This potential
wealth of therapies poses a novel challenge to the
adjuvant trials setting. Multiple potential therapies
will have to be assessed concurrently. Economy of
time, cost, and most importantly patient enrollment
will consequently be crucial to future trials. New
strategies are therefore required, not only with regard
to the biological and pharmacological approaches to
relapse risk reduction in RCC but also with regard to
trial design and resource allocation. Overall, the land-
scape of adjuvant clinical trials in RCC is likely to
expand and diversify further in the years to come.
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